Chengdu Kanghong Pharmaceutical Group Co., Ltd

Equities

002773

CNE1000020C4

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-28 pm EDT 5-day change 1st Jan Change
21 CNY +1.50% Intraday chart for Chengdu Kanghong Pharmaceutical Group Co., Ltd +18.78% +13.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kanghong Pharmaceutical's Unit Gets US FDA's Green Light to Test Macular Degeneration Drug MT
Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023 CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kanghong Pharmaceutical's Mosapride Citrate Tablets Wins Centralized Procurement Bid MT
Kanghong Pharmaceutical's Beijing Unit Gets China's Approval for Clinical Trials for Anti-Tumor Injection MT
Kanghong Pharmaceutical's Unit Gets Nod to Trial Psoriasis Drug MT
Kanghong Pharmaceutical Gets Nod for Registration of Escitalopram Oxalate Tablets MT
Kanghong Pharma's Aripiprazole Oral Solution Chosen for China's Centralized Drug Procurement MT
Kanghong Pharma Gets FDA Nod to Trial Drug Against Fatty Liver Disease MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Kanghong Pharmaceutical Gets US FDA's Clinical Trial Nod for Antidepressant MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Executive Changes CI
Kanghong Pharma Gets Nod to Trial Antidepressant MT
Chengdu Hongji Biotechnology Co., Ltd. announced that it expects to receive CNY 159.736344 million in funding from Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu Kangji Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangyin Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangzhi Technology Consulting Partnership (Limited Partnership) CI
Kanghong Pharma Gets Continued Protection for Traditional Chinese Medicine MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on Share A for 2022, Payable on June 6, 2023 CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Approves Cash Dividend for the Year 2022 CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chengdu Kanghong Pharma Wins Orphan Drug Designation in US MT
Kanghong Pharma’s Eye Drug Added to China’s Medical Insurance Catalog MT
Kanghong Pharma Sees 121% Jump in 2022 Profit MT
Kanghong Pharma Gets Marketing Nod in China for Antidepressant MT
Chart Chengdu Kanghong Pharmaceutical Group Co., Ltd
More charts
Chengdu Kanghong Pharmaceutical Group Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines, chemical drugs and biological products. The Company’s main products include Conbercept Ophthalmic Injection, Songling capsules conducive to blood vessels, Keluoxin capsules, venlafaxine hydrochloride capsules and sustained release tablets, aripiprazole tablets and orally disintegrating tablets, mosapride citrate tablets and dispersible tablets, dexzopiclone tablets, Shuganjieyu capsules, Danshu capsules and Yiqing capsules, among others. The Company distributes its products in domestic market.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
21
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002773 Stock
  4. News Chengdu Kanghong Pharmaceutical Group Co., Ltd
  5. Kanghong Pharmaceutical's Mosapride Citrate Tablets Wins Centralized Procurement Bid